glp gip glucagon & cagrilintide

https://www.medicadepot.com/wp-content/uploads/2026/03/Cagrilintide-5mg-Front.png.webp water Size:90 Softgel Capsules Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease BPC-157 (Body Protection Compound)

BESTSELLER

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review

4.8 / 5 · 27 reviews

USD22.99

NEW

Retatrutide + Cagrilintide Benefits: 4 Pathways (2026)

4.2 / 5 · 25 reviews

USD22.24

glp/gip/glucagon & cagrilintide New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists Treatment:1 Month bpc-157 oral vs injection senior dog –

4.3 / 5 · 26 reviews

USD28.29

BESTSELLER

Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare

4.9 / 5 · 8 reviews

USD27.74

NEW

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

4.6 / 5 · 7 reviews

USD21.99

Amycretin: The Oral Obesity Pill That Could Change Everything About Access to Metabolic Medicine

4.0 / 5 · 20 reviews

USD28.57

NEW

GLP-1 Receptor Agonists – Peripheral Brain

4.6 / 5 · 26 reviews

USD25.14

BESTSELLER

CagriSema: a novel dual-pathway approach to target obesity and its complications

4.0 / 5 · 5 reviews

USD22.82

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart

4.8 / 5 · 6 reviews

USD24.49

NEW

GLP-1, GIP and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy

5.0 / 5 · 12 reviews

USD22.39

BESTSELLER

Amino acid sequence of GLP-1R/GIPR coagonist, DR10627 and the related

4.8 / 5 · 17 reviews

USD29.52

The Glucagon Paradox In Next-Generation Incretin Therapy: GLP-1, GIP, And Glucagon Receptor Co-Agonism GlobalRPH

4.1 / 5 · 5 reviews

USD29.31

NEW

Schematic illustration of monoagonists, dual agonists and triple

4.1 / 5 · 11 reviews

USD26.67

BESTSELLER

Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research

4.7 / 5 · 29 reviews

USD22.84

Triple Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports

4.1 / 5 · 16 reviews

USD23.29

NEW

Major physiological roles of GLP-1 and GIP. Tirzepatide is acting as an

4.1 / 5 · 9 reviews

USD26.24

BESTSELLER

Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports

4.5 / 5 · 30 reviews

USD29.44

NEW

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

4.4 / 5 · 28 reviews

USD20.83

Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements

4.4 / 5 · 19 reviews

USD23.27

BESTSELLER

CagriSema vs Retatrutide: Amylin/GLP-1 Combination vs Triple Agonist Comparison - Which Is Better? | PPW

4.9 / 5 · 30 reviews

USD23.93

Explore related edits